| Basics |
AnaptysBio, Inc.
AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.
|
| IPO Date: |
January 26, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$681.33M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.96 | 2.65%
|
| Avg Daily Range (30 D): |
$0.64 | 2.93%
|
| Avg Daily Range (90 D): |
$0.68 | 3.71%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.3M |
| Avg Daily Volume (30 D): |
.54M |
| Avg Daily Volume (90 D): |
.77M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
60 |
| Avg Trade Size (Sh.) (90 D): |
71 |
| Institutional Trades |
| Total Inst.Trades: |
2,845 |
| Avg Inst. Trade: |
$1.7M |
| Avg Inst. Trade (30 D): |
$1.92M |
| Avg Inst. Trade (90 D): |
$1.69M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.69M |
| Avg Closing Trade (30 D): |
$1.7M |
| Avg Closing Trade (90 D): |
$1.87M |
| Avg Closing Volume: |
52.18K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$-1.28
|
$-1.14
|
|
Diluted EPS
|
|
$-1.28
|
$-1.14
|
|
Revenue
|
$
|
$ 27.77M
|
$ 30.02M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -39.33M
|
$ -32.85M
|
|
Operating Income / Loss
|
$
|
$ -27.54M
|
$ -22.76M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -24.44M
|
$ 119.76M
|
|
PE Ratio
|
|
|
|
|
|
|
